Scholarlink

Background <p>Cerebral small vessel disease (CSVD) causes significant disability at increasing age, such as cognitive impairment, gait, and sphincteric problems affecting a person’s quality of life. That is why it is essential to be detected and managed early. The aim of this study is to investigate clinical and radiological progression among a sample of Egyptian patients with incidental CSVD after a 1-year antiplatelet therapy, either aspirin or cilostazol.</p> Results <p>Regarding the MRI lesions, both visual rating scales and lesion load assessment did not show any significant difference between baseline and follow-up. As for the clinical assessment, there was also no significant difference between the two groups at baseline and follow-up.</p> Conclusion <p>Neither aspirin nor cilostazol had an impact on clinical and radiological progression over 1 year in patients with CSVD. More sophisticated tools are needed to assess radiological progression in CSVD.</p> <p><i>The trial is registered in PACTR No. PACTR202301861240705. </i><a href="https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19331">https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19331</a>. <i>Date of Approval: 31/1/2023.</i></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical and radiological outcome of incidental cerebral small vessel disease using antiplatelet therapy: randomized pilot study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月14日

查看全文
  • Yasmine Hassan Abdelhamid,
  • Eman Hamid,
  • Mena Elerian,
  • Hossam Shokri,
  • Mai Fathy,
  • Tamer Roushdy,
  • Hani Zakieldine,
  • Nevine El Nahas,
  • Hany Aref

摘要

Background

Cerebral small vessel disease (CSVD) causes significant disability at increasing age, such as cognitive impairment, gait, and sphincteric problems affecting a person’s quality of life. That is why it is essential to be detected and managed early. The aim of this study is to investigate clinical and radiological progression among a sample of Egyptian patients with incidental CSVD after a 1-year antiplatelet therapy, either aspirin or cilostazol.

Results

Regarding the MRI lesions, both visual rating scales and lesion load assessment did not show any significant difference between baseline and follow-up. As for the clinical assessment, there was also no significant difference between the two groups at baseline and follow-up.

Conclusion

Neither aspirin nor cilostazol had an impact on clinical and radiological progression over 1 year in patients with CSVD. More sophisticated tools are needed to assess radiological progression in CSVD.

The trial is registered in PACTR No. PACTR202301861240705. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=19331. Date of Approval: 31/1/2023.